PTEN and thyroid cancer: Interestingly, while there was no further anti-migratory benefit of combined treatment of the PTEN-intact lines, a modest but significant reduction was observed in the PTEN-null treated with both PLX4720 and dasatinib relative to treatment with dasatinib alone suggesting that the loss of PTEN confers a more migratory phenotype in these thyroid cancer cell lines.